ADTX Aditxt Corp: מכפיל P/S עתידי

Aditxt is expanding its ecosystem through mergers with biotech startups, yet a critical liquidity shortage and mounting debt threaten the holding company's stability. Data from the GURU.Markets terminal provides a calculated forward P/S, where the 1017.10 figure serves as the target level. Meanwhile, patents in immune monitoring provide Aditxt with the potential to monetize intellectual property through clinical ancillary services.
פילוחים אנליטיים של חברת aditxt.com (ADTX)

The efficiency of the Pears platform in monitoring immune rejection during transplants determines the revenue growth rates of Aditxt, which directly impacts the forward P/S as the ratio of market capitalization to expected sales. By analyzing the Aditxt forward P/S chart, an investor assesses the degree of overpayment for future income, utilizing multiple compression to identify entry points into an undervalued asset.